which was subsequently extracted. The patient tolerated the procedure well, but was seen for multiple post-operative visits due to intermittent pain and swelling of the right side of his face. At a later follow-up appointment, the patient presented with a slightly fluctuant, ulcerated mass of the right hard palate/posterior maxillary alveolar gingiva that was tender to palpation (Fig. 1) . A procedure planned for incision and drainage revealed a firm, yellow nodular mass in the pterygomaxillary recess with mobility of tooth #2 and no purulent drainage. An incisional biopsy was made. Subsequent computed tomography (CT) and magnetic resonance imaging (MRI) revealed a large mass, approximately 5.1 × 3.9 cm in size, in the right infratemporal fossa/ masticator space causing significant boney destruction of the maxillary sinus wall, lateral pterygoid plates, and inferior lateral aspect of the skull (Fig. 2 ). On MRI with and without contrast, the tumor demonstrated two components: one more fibrous or muscular component (darker on T2-weighted images), extending superiorly into the temporalis muscle, and a second component that was bright on T2-weighted sequences growing into and displacing the posterior wall of the maxillary sinus (Fig. 2) . No evidence of metastases was noted on chest and abdomen imaging.
Microscopic examination revealed a mass of hypercellular tissue consisting of cells with hyperchromatic spindled nuclei, occasional perinuclear vacuoles, and abundant pink cytoplasm. The cells were arranged in interlacing fascicles and demonstrated a high mitotic rate of approximately 18 mitoses per 10 high power fields (HPF). Immunohistochemical staining showed cytoplasmic reactivity to desmin, muscle specific actin (MSA), and vimentin in most neoplastic cells, as well as focal, strong nuclear reactivity to myogenin (Fig. 3) . The tumor cells were negative to S-100 protein, α-smooth muscle actin (αSMA), CAM5.2, and AE1/3.
The patient was treated with a partial maxillectomy, partial mandibulectomy towards the skull base, and lateral rhinotomy. He subsequently underwent post-operative chemoradiation. A maxillary obturator was fabricated. The patient subsequently experienced mucositis, dermatitis, and persistent infection secondary to radiation and chemotherapy and emotional distress related to the cosmetic outcomes of the treatment. The patient had not exhibited tumor recurrence 4 years after initial diagnosis.
Case 2
A 39-year-old male patient was previously diagnosed with rhabdomyosarcoma, spindle cell variant of the left buccal mucosa. Prior to that diagnosis, he had no remarkable past medical history. He was treated with a wide local excision, and the surgical margins were found to be negative on examination of frozen sections. He was subsequently treated with chemotherapy. After one and a half years, he noted a small mass in the left buccal mucosa, just inferior to the previous excision site, which was noted on imaging (Fig. 4) . Microscopic examination of the second 5.5 × 4.0 cm buccal mucosa mass revealed fascicles of spindled cells with hyperchromatic, blunt-shaped nuclei. In addition, large, pleomorphic cells were noted throughout the specimen, and occasional plump ganglion-like cells with abundant eosinophilic cytoplasm were present (Fig. 5) . A histopathologic diagnosis of recurrent rhabdomyosarcoma was rendered.
CT imaging noted no mediastinal or hilar adenopathy nor pulmonary nodules. The patient was treated by wide local re-excision and subsequent split-thickness skin grafting. He was seen by the dental clinic for a pre-radiation screening and underwent two molar extractions in preparation for treatment. The patient received 6 weeks of radiation (approximately 6500 cGy).
Three years and 3 months after the excision of the recurrent tumor, the patient exhibited a second recurrence. He subsequently was treated with a composite resection of the mandible including the infratemporal fossa, submandibular gland, and the retromolar trigone. He had difficulties with nausea and vomiting secondary to chemotherapy treatment, as well as cramps and numbness of his hands and toes.
After three excisions for rhabdomyosarcoma, the patient was lost to follow-up 1 year after the last excision.
Case 3
A 22-year-old Caucasian male with no pertinent past medical history presented to his dentist for evaluation of a broken tooth. After extraction of the affected tooth, the dentist noted a soft tissue swelling in the left mandibular area. The patient was treated with antibiotics with no resolution of the swelling. On CT imaging, the patient was found to have a large soft tissue mass located in the left masticator space (Fig. 6) . No evidence of intrathoracic or abdominal metastases was noted. An excisional biopsy was performed. On microscopic examination, the tumor was composed of predominantly intertwining fascicles of spindled cells ( Fig. 7) with plump, blunt-ended nuclei with prominent nucleoli. In some foci, the cells became less spindled and more round to angular in shape. Rhabdomyoblasts (ganglion-cell like and "strap cells") occasionally were seen in this framework. Significant pleomorphism was present throughout the tumor. A brisk mitotic rate of about 20 mitoses per 10 HPF was noted. Notably, prominent myxoid hyalinization/sclerosis of the stroma was present in a significant portion of the tumor. Immunohistochemistry demonstrated positivity to desmin, smooth muscle actin, myogenin, and Myo-D1 (Fig. 8) . The neoplastic cells were negative for S-100 protein.
The patient underwent two cycles of chemotherapy (vincristine, adriamycin, and cyclophosphamide) with no noticeable response. The patient was treated with 7200 cGY of radiation. Additional follow-up visits with imaging to see whether the tumor showed any response to chemotherapy and radiation therapy are planned. 
Discussion
Sarcomas represent approximately 7% of all malignancies occurring in patients under the age of 20 [5, 6] , and of these sarcomas, RMS is the most prevalent, comprising 40-50% [6, 7] . RMS in adults is exceedingly rare [7, 8] . Encompassing all age groups, the current incidence of RMS in the head and neck region is 0.041 cases per 100,000 people, a number that has increased steadily over the past 30 years [9] .
Since the S-ScRMS subtype was recently reclassified as a stand-alone entity, data regarding its clinical course, histopathologic characteristics, genetic abnormalities, and prognosis as a combined subtype is scant. The spindle cell variant demonstrates a predilection for the paratesticular region, followed by the head and neck [10, 11] , while the sclerosing variant tends to involve extremities, then the head and neck [12] . As with all types of RMS, S-ScRMS exhibits a male predilection [2, [11] [12] [13] . Both children and adults are affected in this variant, with a range of 0.3-79 years [4, 12] .
Microscopic examination of S-ScRMS typically reveals a proliferation of spindled to ovoid cells with long and intersecting fascicles. The cells contain a small, elongated nucleus with vesicular chromatin and pale, indistinct cytoplasm. The nuclei may demonstrate small nucleoli or pseudoinclusions. A prominent hyalinized matrix may be present, which may be confused with osteoid or chondroid [12, 14] . When sclerosis is present, the cells may be compressed into cords or microalveolar structures and demonstrate a pseudovascular growth pattern. An important diagnostic clue is the presence of rhabdomyoblastic features, including "strap cells" with cross-striations (Fig. 7d) or ganglion cell-like rhabdomyoblasts, which demonstrate abundant granular, eosinophilic cytoplasm with eccentrically placed nuclei (Fig. 7c) .
Immunohistochemical stains demonstrate distinct positivity for desmin and vimentin. Variable expressivity of myogenin (Myf-4), Myo-D1 (Myf-3), myoglobin, SMA, and MSA has been reported. The diffuse and strong positivity for Myo-D1 in the last case further supports our diagnosis, as Myo-D1 has been shown to be a more sensitive marker for the sclerosing variant of RMS [12, 14] . MDM2, Bcl-2, p53, calponin, and CD56 rarely have been expressed in published cases [12] . RMS is negative for S-100, epithelial membrane antigen (EMA), cytokeratins, glial fibrillary acidic protein (GFAP), caldesmon, vascular markers, neuroendocrine markers, and melanoma markers. Desmin and myogenin together tend to be the most reliable markers for this variant, although positivity may be scattered or "dotlike" for either [14] [15] [16] .
The histopathologic differential diagnosis for S-ScRMS includes synovial sarcoma, leiomyosarcoma, spindle cell carcinoma, spindle cell melanoma, fibrosarcoma, malignant peripheral nerve sheath tumor, and malignant triton tumor. When extensive sclerosis is present, osteosarcoma and chondrosarcoma may also be considered. Immunohistochemistry is most helpful in differentiating RMS from other malignancies since most do not demonstrate myogenin, Myo-D1, or desmin positivity. Leiomyosarcoma may demonstrate desmin positivity, but will not react to myogenin or contain strap cells. Malignant triton tumor, especially those that are S-100 negative, may be difficult to differentiate from RMS, as both have demonstrated desmin, myogenin, and Myo-D1 positivity. Malignant triton tumor, however, will only express these markers in the rhabdomyoblastic regions and not diffusely throughout the specimen. A clinical history of type I neurofibromatosis would be helpful, as many patients with malignant triton tumor have this syndrome [10] ; however, a few cases of RMS also have been associated with neurofibromatosis [17] .
Patients with S-ScRMS demonstrate heterogenic genetic alterations that may have particular importance on prognosis. Tumors diagnosed in infancy frequently exhibit recurrent gene fusions implicating VGLL2, SRF, TEAD1, or NCOA2 and appear to be associated with outcomes that are more favorable [4, 18] . Conversely, a subset of S-ScRMS demonstrate mutations in MYOD1 (some with accompanying PIK3CA mutations). These latter mutations exhibit aggressive clinical courses with higher mortality rates unrelated to the age of the patient. Because of the poorer prognosis associated with MYOD1 mutations, molecular evaluation of this mutation in patients with S-ScRMS has been suggested for risk stratification [4, 13] . Unfortunately, none of the patients described herein underwent molecular studies for MYOD1 mutations.
Most RMS are treated with conventional surgery, chemotherapy, and radiotherapy. Chemotherapeutic agents typically consist of actinomycin D, doxorubicin, ifosfamide, cyclophosphamide, etoposide, or vincristine [19] . Despite efforts at various treatment techniques, the prognosis for RMS, especially S-ScRMS, remains poor [4, 9] , and longterm survival decreases significantly when the patient exhibits recurrence [19] . When patients do survive, longterm sequela from treatment, including facial asymmetry, tooth formation abnormalities, jaw hypoplasia, trismus, and hyposalivation/xerostomia may remain and significantly alter patient's lifestyles [20] . Recent research into immunotherapy using monoclonal antibodies or suicide gene therapy seems promising [19] .
Conclusion
Due to the rarity of cases in the literature and recent reclassification of S-ScRMS, case reports and series are especially valuable to the literature. We report three new cases of S-ScRMS (two cases of spindle cell pattern, and one of spindle cell pattern with sclerosis), all presenting within the oral cavity in adult males. One case demonstrated significant clinical aggressiveness with inability to locally control the tumor. Additional case reports of this RMS variant may help us to not only better understand the clinical behavior and diagnostic challenges, but also to develop more targeted treatment therapies in order to improve long-term survival and quality of life.
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